Pipamperone/antipsychotics

Drug Profile

Pipamperone/antipsychotics

Alternative Names: Clozapine/pipamperone; Paliperidone/pipamperone; Pipamperone/clozapine; Pipamperone/paliperidone; Pipamperone/risperidone; PNB-02; Risperidone/pipamperone

Latest Information Update: 22 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmaNeuroBoost
  • Class Antipsychotics; Butyrophenones; Isonipecotic acids; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Dopamine D4 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Schizoaffective disorder; Schizophrenia

Highest Development Phases

  • No development reported Schizophrenia

Most Recent Events

  • 22 Sep 2015 No recent reports on development identified - Phase-I/II for Schizophrenia (Combination therapy) in Belgium (PO)
  • 21 Dec 2012 PharmaNeuroBoost completes a phase I/IIa trial in Schizophrenia in Belgium (NCT01450514)
  • 01 Mar 2012 Phase-I/II clinical trials in Schizophrenia in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top